News
Sarepta Shares Fall After Gene Therapy Hits Another Regulatory Roadblock
Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the therapies was linked to the death of a 51-year-old man last month.
US FDA Investigates Third Death After Treatment With Sarepta's Gene Therapy Elevidys
The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys. The death occurred on June 7,
Stocktwits on MSN2d
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The AnnouncementArrowhead Pharmaceuticals, Inc. (ARWR) announced on Wednesday that it expects its licensing partner, Sarepta Therapeutics ...
Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...
Dealbreaker on MSN4d
Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...
The financial stakes for Sarepta are significant. Elevidys accounted for 43% of the company’s revenue last year, establishing it as Sarepta’s lead commercial product.
In the preceding three months, 38 analysts have released ratings for Sarepta Therapeutics SRPT, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...
Sarepta's stock drops on ELEVIDYS safety concerns, ... Financial Health. Despite generating $744.9 million in total revenues in Q1 2025, Sarepta reported a net loss of $300.4 million.
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $109.8, a high estimate of $202.00, and a low estimate of $40.00. Highlighting a 20.62% decrease ...
The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also undermining investor confidence in the company that makes it.
Health-care companies fell after a major setback for one gene-therapy firm. The death of a second patient taking Sarepta Therapeutics' controversial gene therapy for Duchenne muscular dystrophy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback